In the liver, induction of genes encoding enzymes involved in de novo lipogenesis occurs in response to increased glucose metabolism. ChREBP (carbohydrate-response-element-binding protein) is a basic helix-loop-helix/leucine zipper transcription factor that regulates expression of these genes. To evaluate the potential role of ChREBP phosphorylation in its regulation, we used MS to identify modified residues. In the present paper, we report the detection of multiple phosphorylation sites of ChREBP expressed in hepatocytes, several of which are only observed under high-glucose conditions. Mutation of each of these serine/ threonine residues of ChREBP did not alter its ability to respond to glucose. However, mutation of five N-terminal phosphoacceptor sites resulted in a major decrease in activity under highglucose conditions. These phosphorylated residues are located within a region of ChREBP (amino acids 1-197) that is critical for glucose regulation. Mutation of Ser 56 within this region to an aspartate residue resulted in increased nuclear accumulation and activity under high-glucose conditions. Together, these data suggest that ChREBP activity is regulated by complex multisite phosphorylation patterns involving its N-terminal regulatory region.
INTRODUCTION
The liver is responsible for directing macronutrients into pathways for utilization or storage, depending on the energy status of the organism. When dietary carbohydrate is in excess, glucose can be converted into triacylglycerols in the liver through the pathway of de novo lipogenesis for long-term storage of energy. Stimulation of this pathway occurs through regulation of the activity and concentration of many enzymes involved in triacylglycerol synthesis. Lipogenic enzymes that are transcriptionally induced in response to a high-carbohydrate diet include L-type pyruvate kinase, ACC (acetyl-CoA carboxylase), fatty acid synthase and stearoyl-CoA desaturase [1] [2] [3] . Insulin is a critical signal for the induction of many of these genes and acts via SREBP1c (sterol-regulatory-element-binding protein 1c) to stimulate transcription [4] [5] [6] [7] [8] . However, it is now appreciated that increased glucose uptake and metabolism in the hepatocyte trigger a distinct signalling pathway that is also critical for this transcriptional induction [9] [10] [11] .
Lipogenic enzyme genes that respond transcriptionally to increased glucose metabolism possess a regulatory element known as a ChoRE (carbohydrate-response element) in their promoter region [12] [13] [14] [15] [16] [17] . The ChoRE consists of two E box-like sequences (CACGTG) separated by 5 bp. These E box elements are recognized by two heterodimers of the basic helix-loophelix/leucine zipper transcription factors ChREBP (ChoRE-binding protein) and Mlx that bind co-operatively to the ChoRE [18, 19] . Of these two, ChREBP is most likely the direct target of glucose signalling [20] [21] [22] . It is expressed at the highest levels in liver and adipose, tissues capable of regulated lipogenesis [21] . In addition, fusion of ChREBP-coding sequences with the DBD (DNA-binding domain) of Gal4 yields a glucose-responsive factor [23, 24] . The role of Mlx appears to be to target ChREBP to appropriate genes by supporting its recognition of the ChoRE [25] .
ChREBP contains several consensus phosphorylation sites for PKA (protein kinase A). It has been proposed that the phosphorylation status at three PKA sites is responsible for the regulation of ChREBP [26] . Under fasting conditions, phosphorylation at Ser 196 was shown to restrict ChREBP to the cytoplasm, whereas phosphorylation at Ser 626 and Thr 666 inhibited its DNA binding [26] . Under conditions of increased glucose availability, reversal of these inhibitory phosphorylation events via PP2A (protein phosphatase 2A) results in nuclear localization and DNA binding of ChREBP. The activity of PP2A was suggested to be activated by the metabolite xylulose 5-phosphate, which accumulates in response to elevated glucose metabolism [27] .
In contrast, studies from our laboratory and from others have challenged several aspects of this model. We have shown that total phosphorylation of ChREBP does not decrease under high-glucose conditions, as proposed by the current model [28] . Furthermore, preventing PKA-mediated phosphorylation by mutating Ser 196 , Ser 626 and Thr 666 to alanine does not create a glucose-independent (constitutive) active form under low-glucose conditions in hepatocytes [28] or β-cell-derived INS-1 cells [23, 24] . These findings suggest that other regulatory mechanisms must exist.
For these reasons, we set out to identify residues of ChREBP that are phosphorylated in cells and to determine whether these sites are essential for its glucose-induced activation. We identified multiple sites of phosphorylation that are located at regions within or near proposed regulatory domains of ChREBP. Blocking or mimicking phosphorylation at several of these sites influenced glucose activation of ChREBP, suggesting a critical role for phosphorylation in regulating its function.
MATERIALS AND METHODS

Primary hepatocyte culture and transduction
Male Sprague-Dawley rats (250-300 g) were fed ad lib., and primary hepatocytes were isolated using the collagenase perfusion method described previously [29] . After 3-4 h, cells were transduced with recombinant adenovirus for 2 h in Medium 199 containing 5.5 mM glucose, 23 mM Hepes, 10 nM dexamethasone, 2 mM glutamine, 50 units/ml penicillin, 50 μg/ml streptomycin, 26 mM sodium bicarbonate and 0.1 unit/ml insulin (low-glucose medium). Hepatocytes were transduced with adenovirus expressing either FLAG-tagged WT (wild-type) ChREBP (ζ isoform, GenBank ® accession number AF245475) or a S196A/S626A/T666A triple mutant (TM) ChREBP adenovirus, along with the obligate heterodimer partner Mlx (β isoform, GenBank ® accession number AF213671) and maintained in low-glucose medium for 24-36 h [28] . Subsequently, cells were treated with high-glucose medium (identical with lowglucose medium except the glucose concentration was 25 mM), 100 μM pCPT-cAMP [8-(4-chlorophenylthio)adenosine 3 :5 -cyclic monophosphate] or 25 mM mannitol (osmolarity control) for 2-4 h before harvest.
Immunoprecipitation and MS of ChREBP phosphopeptides
Following incubation, cells were harvested in RIPA buffer (50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 % Nonidet P40, 0.1 % SDS, 0.5 % deoxycholate, 50 mM NaF, 1 mM EDTA) plus Complete TM protease inhibitors minus EDTA (Roche) and 0.25 μM microcystin (Sigma). Whole-cell extracts were immunoprecipitated with anti-FLAG antibody resin (Sigma) overnight. Immunoprecipated material was washed three times with RIPA buffer and eluted with SDS loading buffer. Samples were electrophoresed on a 10 % polyacrylamide/SDS gel and stained with Coomassie Blue. Bands that were observed only in the presence of FLAG-tagged ChREBP were excised from the gel and digested with trypsin or chymotrypsin overnight. Digested peptides were run through ESI (electrospray ionization)-LC (liquid chromatography)-MS/MS (tandem MS) on a LTQ linear ion-trap mass spectrometer (Thermo Scientific). An inclusion list was generated for mono-or di-phosphorylated ChREBP/Mlx peptides. Peptides were identified using the Seaquest search database, along with manual confirmation of ions.
Construction of mutant ChREBP constructs
dnChREBP (dominant-negative ChREBP) was constructed using the QuikChange ® site-directed mutagenesis kit (Stratagene) by inserting a double mutation (R673A/R674G) into the basic region of the DBD. This mutant was used to prepare an adenoviral vector as described previously for dominant-negative Mlx [30] . Site-specific mutations of ChREBP used in rescue assays were constructed in the same manner, but the template used was CMV4-FLAG-tagged ChREBP [28] or pSG424 [31] fused with ChREBP. The mutations and coding sequences were confirmed by DNA sequencing. Immunoblotting of ChREBP from transfected HEK-293 (human embryonic kidney) cells was performed using anti-FLAG (F3165; Sigma) or anti-Gal4 (sc-510; Santa Cruz Biotechnology) antibodies to ensure that each construct was expressed at comparable levels.
Transcriptional reporter gene assays for measuring ChREBP activity
Hepatocytes were cultured in six-well CellBind plates (Corning) and transduced with adenovirus expressing the dnChREBP. The amount of virus used was determined empirically to give approx. 90 % inhibition of the glucose response. After 2 h, hepatocytes were transfected using F1 reagent (Targeting Systems) in lowglucose medium. A mixture of firefly luciferase reporter (2 μg) driven by an ACC ChoRE-containing promoter region [28] and a Renilla luciferase (pRL-CMV; Promega) control plasmid (25 ng) were co-transfected with 125 ng of each expression plasmid for ChREBP as described previously [30] . Cells were cultured in low-glucose medium for an additional 24 h to allow expression of recombinant proteins. Subsequently, cells were maintained in low-glucose medium or switched to high-glucose (27.5 mM) or pCPT-cAMP (100 μM), and hepatocyte lysates were harvested the following day in Passive Lysis Buffer (Promega). Dualluciferase assays were performed following the manufacturer's instructions.
EMSAs (electrophoretic mobility-shift assays)
HEK-293 cell culture and transfections for EMSAs were performed in a similar manner as described previously [32] . For whole-cell extracts used in EMSAs, HEK-293 cells were cotransfected using Lipofectamine ® 2000 with 2.5 μg of WT or mutant ChREBP construct and 1.5 μg of Mlx, both in the CMV4 vector. Whole-cell lysates were prepared from cells 40-48 h post-transfection using the 'whole-cell extract' protocol (Active Motif). A typical reaction contained 100 000 c.p.m. of 32 P-labelled ACC ChoRE [16] oligonucleotide and 5 μg of whole-cell extract. For the reaction with antibody, whole-cell extracts were first incubated with 3 μg of anti-FLAG antibody (Sigma) for 15 min at 4
• C. Reactions were incubated with oligonucleotide for 25 min at 25
• C and were separated on 5 % non-denaturing polyacrylamide gels.
Immunolocalization analysis of ChREBP
INS-1 cells (832/13 subclone, a gift from Dr C. Newgard, School of Medicine, Duke University, Durham, NC, U.S.A.) were cultured as described previously on an eight-chamber glass slide and grown to 70 % confluence [33] . Cells were then cotransfected with 0.15 μg each of WT or mutant ChREBP and Mlx using Lipofectamine ® 2000 and 1.1 μl of Virofect (Targeting Systems). After incubation of transfected cells overnight in 11 mM glucose, cells were maintained in RPMI 1640 medium containing 2.5 mM glucose for 4 h and then treated with 25 mM glucose for 2 h. Cells were then fixed in 1.6 % (v/v) formaldehyde and 0.2 % Triton X-100, washed with 1× PBS, 0.2 % Triton X-100 solution and incubated overnight at 4
• C. The slides were then blocked with 10 mg/ml BSA, 1× PBS, 0.2 % Triton X-100 and 5 μl/ml donkey serum (Jackson ImmunoResearch Laboratories). Following the block, cells were incubated with 0.25 μg of anti-FLAG monoclonal antibody for 1 h at 37
• C, washed five more times and incubated with secondary FITC-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories) for an additional 1 h. Nuclei were stained with TO-PRO-3 TM (Invitrogen) during the final wash steps. Cells were imaged using a multi-photon confocal microscope (Fluoview 1000; Olympus).
RESULTS
ChREBP is phosphorylated at multiple residues
To characterize phosphorylation sites on ChREBP, we used MS to select potentially modified peptides and MS/MS to identify the specific residues modified within these peptides. Because of the low levels of endogenous ChREBP present in cells, we analysed a FLAG-tagged ChREBP that was introduced into hepatocytes using an adenoviral vector. The FLAG epitope was inserted at the N-terminus of ChREBP and resulted in the loss of amino acids 2-4 of ChREBP. We have found that this form behaves identically with WT ChREBP in supporting a glucose response [18] . Although it is slightly modified, we will refer to this form as 'wildtype' in this study to distinguish it from many mutant forms of ChREBP analysed. FLAG-ChREBP was transduced into primary hepatocytes together with an adenovirus expressing Mlx. In preliminary experiments, we found that co-expression of Mlx resulted in increased recovery of ChREBP. We used two forms of ChREBP for this analysis: WT and TM. The rationale for using the triply mutated form of ChREBP was to optimize detection of phosphorylation sites distinct from the proposed PKA target residues.
Proteins were immunoprecipitated using anti-FLAG antibody resin and observed using SDS/PAGE and Coomassie Blue staining. Four unique bands were observed from cells transduced with ChREBP-expressing adenovirus compared with an empty vector viral control (see Supplementary Figure 1 at http://www. BiochemJ.org/bj/411/bj4110261add.htm). These bands were excised, digested with protease and analysed using ESI-LC-MS/MS. The FLAG-ChREBP migrates just above the expected size of ∼ 95 kDa. The band of ∼ 40 kDa represents an N-terminal fragment of ChREBP that we presume is generated by proteolytic cleavage during processing. In addition, the unique band at ∼ 30 kDa was identified as Mlx, which forms a dimer with ChREBP. The ∼ 70 kDa band was found to be heat-shock protein 8 by MS analysis and may be non-specifically associated with ChREBP. Any peptides from the first MS step that yielded the expected mass for ChREBP with or without phosphorylation were analysed further.
Depicted in Figure 1 are representative MS/MS spectra for two phosphorylated ChREBP peptides containing modified Ser 25 or Ser 56 residues, as well as the spectrum for the unmodified peptide containing Ser 56 for comparison. In both spectra for the phosphorylated peptides, parental ions had the predicted masses from the amino acid composition of ChREBP plus a phosphate group. Parental ions were subjected to fragmentation and MS/MS to confirm their identity and map phosphorylated residues. All y and b ions for fragments preceding the phosphorylated residue correspond to the predicted masses for ChREBP. Those with the phosphorylated residue differ by the additional mass of the phosphate group. It is important to point out that both singly and doubly charged ions are found in the MS/MS spectra. Using a similar strategy, the MS/MS results allowed us to determine that Ser 25 was phosphorylated relative to the other serine or threonine residues in this peptide. Thus Ser 25 and Ser 56 are bona fide sites of phosphorylation for ChREBP. In addition to residues 25 and 56, several additional serine or threonine phosphorylation sites were detected on the basis of the MS/MS spectra of phosphopeptides from hepatocytes cultured in low or high glucose (Table 1) . Eight sites (underlined in Table 1 ) have been detected on three separate occasions and yielded spectra that allowed manual confirmation of the exact residue modified with high confidence. Four additional sites are considered to be tentative assignments, either because the peptides were detected less than three separate times or because of ambiguity in the assignment of the site due to the absence of critical MS/MS ions. The location of each site with respect to functional domains of ChREBP is shown in Figure 2(a) . Phosphorylation sites are found throughout ChREBP, except for the C-terminal Mlx-homology region. Phosphorylation sites are clustered in the N-terminal MCR (Mondo conserved region) region, a region remarkably conserved between ChREBP from a wide variety of species and between ChREBP and its paralogue, MondoA [34, 35] . In addition, a number of phosphorylation sites were found preceding the DBD.
The total coverage of peptides for all of the ChREBP MS/MS analyses combined is depicted in Figure 2 (b). Total coverage was ∼ 70 % using trypsin (shaded grey) and increased to ∼ 87 % when chymotrypsin was used for digestion (underlined). The majority of phosphopeptides were detected under both low-and high-glucose conditions. However, phosphopeptides containing Ser 23 , Ser 140 and Ser 643 were only observed in high-glucose-treated cells. This potential increase in phosphorylation of these sites supports our previous studies in which we found that overall phosphorylation of ChREBP increased by approx. 30 % under high-glucose conditions [28] . However, these observations must be interpreted cautiously, as the lack of evidence does not prove that these three sites were not phosphorylated in cells under lowglucose conditions. Additional regions of ChREBP (unshaded/not underlined in Figure 2b ) that contain serine and threonine residues were not represented in the analysis, and any modifications present on these peptides would have been missed.
In addition to the effects of altered glucose concentrations on ChREBP phosphorylation, we also examined whether cAMP treatment resulted in detection of newly modified sites. Hepatocytes treated simultaneously with high glucose plus cAMP fail to induce ChoRE-containing promoters. We recently reported that the TM ChREBP was only partially able to overcome this inhibition [28] . This suggests that at least one additional regulatory site exists that is responsive to cAMP and presumably phosphorylated by PKA. cAMP was added to hepatocytes for 2 h to assess the effects of cAMP on phosphorylation. 196 , and this peptide was never detected in the cAMP-treated cells. As for Thr 666 , its peptide was detected, but was never modified under any culture conditions. Thus we cannot confirm that these postulated PKA sites are phosphorylated in cells.
Importance of the N-terminal region of ChREBP for glucose regulation
Recently, Chan and co-workers reported that the ChREBP fragment from 1 to 482 was capable of supporting a glucose response when linked to a Gal4 DBD in the pancreatic β-derived Figure 3 (a), a fusion of full-length WT ChREBP with the Gal4 DBD was highly responsive to glucose in hepatocytes, giving a 20-fold induction in response to 27.5 mM glucose on a reporter construct containing five copies of the (a) Each phosphorylation site identified is represented relative to domains of ChREBP [34] . bHLH/LZ, basic helix-loop-helix/leucine zipper; Pro-rich, proline-rich domain; Mlx, Mlx homology region. (b) From all of the MS/MS analyses performed, ∼ 87 % total coverage was achieved for ChREBP. Peptides generated using trypsin are shaded grey, whereas those detected using chymotrypsin are underlined. Phosphorylated serine and threonine residues are shaded black. The FLAG sequence is italicized at the beginning of the sequence.
Gal4-recognition site. As controls, no enhanced promoter activity was observed with a construct expressing the Gal4 DBD by itself, whereas the Gal4 DBD fused to an AH (acidic helix) activation domain [36] resulted in comparable promoter activity in both low and high glucose. We prepared a deletion construct of ChREBP that retained residues 1-482 fused to the Gal4 DBD. This construct also supported a strong (∼ 10-fold) increase in promoter activity under high-glucose conditions. Hence, the Nterminal region of ChREBP from 1 to 482 is capable of mediating the glucose response in both INS-1 cells and hepatocytes.
The N-terminal region of ChREBP contains both putative NLS (nuclear localization signal) (residues 157-175) and NES (nuclear export signal) regions (residues 86-95) nested in a highly conserved portion of the protein (see Figure 2a) . To localize further the critical region for glucose regulation, we prepared deletions of the ChREBP-(1-482) construct by successively removing the coding sequence from the N-terminal end. The fusion construct of ChREBP-(197-482) with the Gal4 DBD gave a very high level of promoter activity in both low and high glucose, as had been observed in INS-1 cells [23] (Figure 3b) . Hence, the first 197 amino acids of ChREBP are critical for the glucose regulation and appear to act in a negative manner to repress the activity under low-glucose conditions in both β-cells and hepatocytes. Similarly, constructs containing residues 137-482 and 165-482 were constitutively active, although somewhat less potent than the 197-482 construct. On the other hand, deletion of residues 1-40 did not interfere with the ability to respond to glucose. However, removal of residues 41-57 resulted in the loss of glucose responsiveness and very low activity of the reporter gene. We conclude that glucose effects are mediated through the N-terminal region of ChREBP, and residues 41-57 are critical for this response.
Mutational analyses of phosphorylated residues of ChREBP
Each individual phosphorylated residue identified in the MS/MS analysis was mutated to either an alanine residue to block phosphorylation or an aspartate residue to potentially mimic phosphorylation. These mutants were then tested for their effect on the activity of ChREBP under low-and high-glucose conditions. Each mutant construct was expressed in HEK-293 cells to ensure that it gave a product with the appropriate size and was expressed at comparable levels (see Supplementary  Figure 3 at http://www.BiochemJ.org/bj/411/bj4110261add.htm). In addition, each mutant ChREBP was tested by EMSA to ensure that its DNA-binding activity was unaffected by the mutation (see Supplementary Figure 4 at http://www.BiochemJ.org/bj/411/ bj4110261add.htm). To assess the effects of mutations on ChREBP activity, we utilized two different functional assays that allowed us to measure the glucose-responsive activity of mutant forms of ChREBP relative to WT ChREBP. In the rescue assay [30] , endogenous ChREBP was inhibited by transducing hepatocytes with adenovirus expressing dnChREBP. Subsequently, cells were co-transfected with a reporter gene containing multiple copies of the ChoRE from the ACC gene linked to a basal promoter and a plasmid expressing either WT or mutant ChREBP. Since this plasmid carries a strong viral enhancer/promoter to drive expression of ChREBP, it can overcome the actions of the dnChREBP by mass action (Figure 4a ). The extent of rescue varied from 50 to 100 % in assays performed in different preparations of hepatocytes. The second assay that we used involved testing fusions of mutant ChREBP with the Gal4 DBD, as described above.
Of all the alanine and aspartate single-site mutants constructed, we observed that the majority of these mutants showed activity that was comparable with that of WT ChREBP. An example using the rescue assay for several single-site ChREBP mutants is shown in Figure 4 (a). The activity for each construct under low glucose was also tested, but was not different than that observed for WT ChREBP (results not shown). Only one mutant (S56D) showed a more robust activity in rescuing the response under high-glucose conditions compared with WT ChREBP. In this case, the S56D mutation resulted in a 4-fold activation above that of WT ChREBP. However, the S56A mutant behaved similarly to WT ChREBP, indicating that phosphorylation of this site alone is not essential for glucose regulation. The increased activity of the S56D ChREBP mutant was also observed in the Gal4 fusion assay (Figure 4b ). The S56D mutant was expressed comparably with WT ChREBP, and its binding to a ChoRE-containing oligonucleotide was normal (see Supplementary Figures 3 and 4) . Hence, its increased activity is likely to be due to enhanced transcriptional potential. Two other single mutants, T311D and S614A, displayed a modest increase in activity (∼ 2-fold) relative to the WT, suggesting that the phosphorylation status at these sites may modulate ChREBP activity as well. Given the modest effect of these mutations, they were not pursued further. Each mutant that is not represented in Figure 4 was also tested for activation and gave the same transcriptional activity as WT ChREBP (results not shown). Overall, we conclude that the phosphorylation status of Ser 56 , and possibly Thr 311 and Ser 614 , is important for optimal activation of ChREBP under high-glucose conditions, but are not critical for the inactivity of ChREBP under low-glucose conditions.
Given the importance of the N-terminal region (amino acids 1-197) of ChREBP to its glucose regulation, we considered the possibility that multiple sites of phosphorylation in this region might control its activity. To test this possibility, we made a mutation in which the five detected phosphorylation sites in this region were simultaneously changed to alanine residues. This mutated ChREBP (S23A/S25A/S56A/S140A/T147A) was dramatically decreased in supporting glucose activation at any concentration tested ( Figure 5 ). This mutant ChREBP was expressed comparably with WT ChREBP. Furthermore, it was capable of binding to a ChoRE-containing oligonucleotide comparable with WT ChREBP by EMSA (results not shown). Hence, a combination of potential phosphoacceptor sites in the N-terminal region of ChREBP is important for its glucose regulation.
Mutation of Ser 56 of ChREBP alters its cellular localization
Since the N-terminal region of ChREBP has been implicated in nucleocytoplasmic shuttling, we analysed the Ser 56 mutants using immunofluorescence in glucose-responsive INS-1 cells to determine whether cellular localization was altered. Owing to technical limitations, we have not been able to use hepatocytes to perform immunofluorescence studies. However, INS-1 cells support a glucose response to ChoRE-containing promoters similar to hepatocytes and represent a valid cell model to study ChREBP regulation [22, 37] . In addition, we found that the S56D mutation of ChREBP was also more active than WT ChREBP in INS-1 cells (see Supplementary Figure 5 at http://www.BiochemJ.org/bj/411/bj4110261add.htm). To assess the localization of ChREBP, we transfected INS-1 cells with either WT or mutant ChREBP expression plasmids. After 24 h, cells were either cultured in low glucose or treated with high glucose for 2 h. Cells were then fixed, and FLAG-tagged ChREBP was detected by immunofluorescence and confocal microscopy. For WT ChREBP, we observed a predominantly cytoplasmic signal in INS-1 cells under low-or high-glucose conditions (Figure 6a ). This probably reflects the presence of an NES within ChREBP, causing the protein to be actively exported from the nucleus. A similar observation has been reported previously in INS-1 cells [23] . Figure 6 (a) shows sample confocal microscopy images for the S56D mutant in low or high glucose. Like WT ChREBP, the S56D mutant was found mostly in the cytoplasm under lowglucose conditions. However, the S56D mutation displayed a marked increased in nuclear accumulation under high-glucose conditions. Quantification of these data revealed that 70 % of cells transfected with the S56D mutant had a predominantly nuclear localization in high glucose, whereas 22 % of the cells showed both nuclear and cytoplasmic staining (Figure 6b ). For the WT ChREBP, 72 % of the cells showed predominantly cytoplasmic staining and only 5 % showed predominantly nuclear signal. Localization studies with many of the other single-site mutations of ChREBP demonstrated cellular distributions indistinguishable from that of WT ChREBP, with the exception of T311D, which also displayed increased nuclear accumulation in high glucose (results not shown). These observations indicate that nuclear accumulation was significantly increased for ChREBP carrying the S56D and T311D mutations and could account for their increased transcriptional activity under high-glucose conditions.
DISCUSSION
ChREBP/Mlx has emerged as the key glucose-responsive transcription factor complex in liver. This complex binds to the ChoRE found in the promoters of many glucose-responsive genes, in particular for genes involved in de novo lipogenesis [18] . In addition, increased occupancy of ChoRE-containing chromatin regions for the pyruvate kinase and fatty acid synthase genes has been observed in β-derived cells cultured under high-glucose conditions [24, 38] . Under conditions of elevated glucose metabolism, ChREBP/Mlx mediate a transcriptional induction of these promoters. The molecular mechanisms involved in activation of ChREBP/Mlx by enhanced glucose metabolism are unresolved. Recently, we reported that ChREBP is phosphorylated and that relative levels of phosphorylation change in response to treatment of hepatocytes with cAMP or elevated glucose [28] . Hence, changes in phosphorylation of ChREBP might account for its regulation by cAMP and glucose. To explore this possibility, it was critical to first map specific sites of phosphorylation in ChREBP.
We detected 12 sites of phosphorylation in ChREBP. Eight specific sites of phosphorylation were assigned with high confidence. Additional phosphorylated residues were assigned tentatively ( To determine whether these sites were important for ChREBP activation in response to elevated glucose, we mutated each individual phosphorylated residue identified in the MS/MS analysis to either an alanine or an aspartate residue. No singlesite mutant showed activation of ChREBP under low-glucose conditions or a loss of activation in the presence of high glucose. Hence, phosphorylation of any individual residue is not essential for the glucose response. We considered the possibility that glucose control of ChREBP involves multiple phosphorylation (or dephosphorylation) events that need to occur sequentially or simultaneously. To evaluate this possibility, we first wanted to identify the region of ChREBP that is involved directly in glucose signalling. Li et al. [23] reported recently that glucose regulation in β-cells can be mapped to the N-terminal region of ChREBP from amino acids 1-298. Within this region, residues 1-197 repressed ChREBP activity under low-glucose conditions, whereas residues 197-298 were involved in glucose-responsive activation. We have confirmed these findings in the context of the hepatocyte and mapped further the critical residues for control by glucose. In particular, amino acid residues 41-58 play an essential role. Deletion of these sequences converted ChREBP into a form unresponsive to glucose. Progressively adding back residues between 58 and 197 sequentially increased activation function, but in a glucose-independent manner. Hence, residues 41-58 are essential for the ability of ChREBP to sense glucose, whereas the region 58-197 provides activation function. Within the N-terminal region of ChREBP, five phosphorylation sites were detected. When all five sites were mutated to alanine residues, the transcriptional activity of this mutant ChREBP was significantly decreased. We have shown that this mutant ChREBP is expressed, binds to the ACC ChoRE, and enters the nucleus (results not shown), similarly to WT ChREBP. The reduced activity of this mutant ChREBP could be due to its inability to overcome repression under low-glucose conditions or to bind to essential cofactors under high-glucose conditions. Since a modest glucose response was still observed for this mutant ChREBP, we favour the latter possibility. Thus phosphorylation of ChREBP in the MCR may contribute to its activation potential, but is unlikely to be the primary signal for glucose control.
Several explanations might account for the lack of effect of phosphoacceptor site mutations on glucose regulation. One possibility is that a critical phosphorylation site for ChREBP regulation may occur in a region not covered in our analysis. It is also possible that we missed the critical time point for a regulatory phosphorylation event. Our analysis was conducted at 2-4 h after treatment with high glucose or cAMP. At this time, the increased accumulation of several glucose-responsive mRNAs is maximal, suggesting that transcription is strongly induced [41] . Furthermore, we have detected phosphorylation of three sites exclusively under high-glucose conditions at this time point. However, an earlier critical phosphorylation of ChREBP could occur in a transient manner, resulting in its prolonged activation. Finally, it is possible that regulation of ChREBP could involve direct modification of another protein that interacts with ChREBP to control its activity. For example, a co-repressor may need to become disassociated from ChREBP to render it active and could be the direct target for glucose regulation. Clearly, further analysis will be necessary to distinguish between these possibilities.
Although no mutation of ChREBP completely blocked its ability to respond to glucose, the S56D mutant ChREBP gave a robust increase relative to WT ChREBP. This increase was observed in both hepatocytes and INS-1 cells and in two different assays for ChREBP activity. In addition, S56D showed increased nuclear localization relative to WT ChREBP in high glucose. Therefore changes in the phosphorylation status of Ser 56 within the essential region 41-58 may serve to modulate ChREBP activity. It is possible that this site could be modified in response to other signals that work in conjunction with glucose to control ChREBP activity. Hormones, such as thyroid hormone and insulin, and other nutrients, such as polyunsaturated fatty acids, influence the ability of glucose to induce gene transcription. By modifying the activation potential of ChREBP, these agents could influence its ability to induce lipogenic gene expression. It should be noted that Ser 56 does not lie within or adjacent to either the putative NES or NLS of ChREBP. The basis of its increased nuclear accumulation is not known, but may result from increased nuclear retention due to its interaction with a transcriptional cofactor.
Our current data, as well as recent data from the Chan laboratory [23] , point to a complex model for ChREBP activation. Based on the Gal4-ChREBP fusions, the N-terminal region of ChREBP is critical for glucose regulation and acts to repress its activity under low-glucose conditions. This suggests that residues 1-197 of ChREBP interact with another protein (or perhaps another region of ChREBP itself) to inhibit its activity. One possibility is that a protein binds to this region of ChREBP to promote its nuclear export or to repress its transcriptional activation. This region of ChREBP contains five of the detected phosphorylation sites. These sites are candidates to facilitate the interaction of ChREBP with the repressor protein through a multisite phosphorylation mechanism. In particular, the region containing residues 41-58 appears to play an essential role in sensing glucose. We propose that this region interacts with a glucose-sensitive repressor. The phosphorylation at Ser 56 may reduce interaction of the 1-197 region of ChREBP with the repressor, as S56D increases activity and accumulates in the nucleus. Further analysis of the N-terminal region of ChREBP will be necessary to test this model.
